Emil Kraepelin's demarcation between dementia praecox and manic depressive illness defi ned aff ective disorder as a remitting and recurring disease. He considered that only long-term outcome was useful in assessing accuracy of diagnosis and treatment response in patients. 1 The more recent interest in the outcome of single mood episodes probably indicates motives to register and market drugs rather than assisting clinical practice. This interest has resulted in many 4-8 week randomised trials but few well designed long-term studies in patients with depression.
There is now increasing evidence that Kraepelin was right. Mood disorders are generally recurring, and the relevant measure of clinical success is long-term Depression relapse: importance of a long-term perspective after catheter removal; infections and febrile episodes potentially related to treatment; catheter blockage; extended hospital stay; and residual incontinence at 3 months. 7 day bladder drainage after repair of simple fi stulas was therefore found to be non-inferior to 14 day drainage, indicating that 7 day drainage is a safe and eff ective way to manage postoperative bladder drainage without any substantial increase in complications. The crucial stage in wound healing, that is mobilisation of fi broblasts, granulation formation, and neovascularisation, occurs at 5 days, with infl ammation generally resolving after 7 days. 2, 6 The fi ndings of Barone and colleagues' study 1 will be welcome news to fi stula surgeons who have agonised over the absence of capacity to care for patients, and the fact that patients with fi stulas are often relegated to the bottom of theatre lists 4 that are frequently loaded with emergencies. Reduction of postoperative catheterisation from 14 days to 10 days without a substantial increase in failure has been estimated to increase the number of patients with fi stulas undergoing surgical repair by almost 30% 3 without any increase in capital investment. 3, 4 Because duration of bladder catheterisation is a key determinant of the length of hospital stay, which aff ects treatment costs and use of hospital beds, 6-9 a halving of the duration of bladder drainage would increase the turnover of women getting the opportunity for care. However, possible confounding factors such as inadequacy of consumable supplies, anaesthesia, and nursing services would need to be addressed 3, 4, 8 for the full benefi ts of such a change in practice to be realised. The socioeconomic benefi t of reduced hospital stay, from the perspectives of both patients and health systems, can be enormous in the setting of poorly resourced countries. 4 A shortened duration of bladder drainage after simple fi stula repair without an increase in the number of breakdowns is most welcome news to patients with fi stulas and their caregivers. If the results of Barone and colleagues' study can be reproduced in another multicentre randomised controlled trial, adoption of its conclusions into clinical practice would substantially expand our capacity to care for patients with fi stulas. My hope is that, in the near future, obstetric fi stula surgeons will have the evidence-based confi dence to reduce the duration of postoperative bladder drainage without any anxiety about increased repair breakdowns.
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Department of Obstetrics and Gynecology, Korle-Bu Teaching Hospital, PO Box KB 36, Korle-Bu, Accra, Ghana atlassey@yahoo.co.uk I declare no competing interests. functioning rather than the outcome of a single mood episode. 2 In secondary and tertiary care, less than a third of patients recover and remain well in the 18 months after an episode of depression, 3 whereas in general practice and community studies, the proportion of patients with recurrence is between 35% and 65%. 4 Treatment needs to focus on maintenance and prevention of relapse as well as on the acute mood episode.
The most established treatment for prevention of relapse and recurrence is maintenance antidepressant medication. Studies have consistently reported a reduction in the odds of relapse of about 50-70%. 5, 6 However, many patients might not wish to remain on medication or cannot tolerate the side-eff ects. Alternative non-medication strategies would obviously be desirable.
Mindfulness-based cognitive therapy (MBCT) was developed as an explicit intervention to reduce relapse and recurrence in depression. MBCT teaches people who have had depression that negative feelings and thoughts will recur and that, rather than worrying or ruminating about these experiences, it is possible to become aware of and disengage from them, thereby preventing a downward spiral into depression. 7 Although cognitive beh avioural therapy and interpersonal therapy also have evidence of effi cacy in the prevention of relapse in depressed patients 8 neither were developed specifi cally for this purpose.
Willem Kuyken and colleagues' study, 9 published in The Lancet, of mindfulness-based cognitive therapy in the prevention of depressive relapse or recurrence is therefore timely. It is a pragmatic long-term study done in general practice, where most depression is treated. The randomised trial compared MBCT with maintenance antidepressants in a large sample of patients with recurrent depression in the UK. 212 patients were randomly assigned to MBCT and 212 to maintenance antidepressant treatment, and the time to relapse or recurrence of depression did not diff er between treatment groups over 24 months (hazard ratio 0·89, 95% CI 0·67-1·18). The authors' interpretation of the fi ndings is carefully worded: there is no support for MBCT being superior to maintenance antidepressants in preventing depressive relapse. Despite this apparent negative result, the fi ndings have substantial clinical signifi cance.
Kuyken and colleagues' fi ndings, if benchmarked against the studies of maintenance antidepressant therapy, provide evidence that MBCT might off er a similar ongoing protective eff ect as that of maintenance antidepressants. MBCT therefore provides an alternative eff ective treatment for patients who cannot tolerate or do not wish to have maintenance antidepressant therapy. Because it is a group treatment that reduces costs and the number of trained staff needed, it might be feasible to off er MBCT as a choice to patients in general practice. Pooling all trial data comparing MBCT and maintenance antidepressant treatment (which is limited to three studies), as Kuyken and colleagues did, 9 resulted in a risk reduction of 24% for MBCT compared with maintenance antidepressants (risk ratio 0·76 95% CI 0·59-0·98). Perhaps all patients with recurrent depression should be off ered MBCT.
We therefore have a promising new treatment that is reasonably cost eff ective and applicable to the large group of patients with recurrent depression. The next obvious question is whether there are specifi c eff ects of MBCT that confer this decreased risk of relapse or whether any structured group psychotherapy would produce similar results. Ongoing studies of mechanism of action are promised by the authors. If the research in long-term treatment of personality disorders is any guide, they are likely to fi nd that general factors such as a manualised approach, active supportive therapists, a focus on patients' sense of agency and management of life situations are most important, 10 rather than specifi c factors related to mindfulness theory. www.thelancet.com Vol 386 July 4, 2015
What do I know? That question was the impulse behind Michel de Montaigne's essays. Whether he was writing about illness, vanity, drunkenness, or sleep, Montaigne wrote with informality, intimacy, and incisive knowledge. As another great essayist William Hazlitt said of Montaigne, "he did not set up for a philosopher, wit, or orator or moralist but he became all these by merely daring to tell us whatever passed through his mind". In the centuries since Montaigne mastered this form, the essay, a discursive and intimate form of personal refl ection, has remained a powerful way to inform, engage, and entertain readers.
So what do you know? And why does it matter to clinical medicine or global health now? We want you to tell us by entering The Lancet's annual essay competition, the Wakley Prize-named after Thomas Wakley, the radical founding Editor of The Lancet. The Prize will be awarded to the best essay on any clinical topic of importance to health. Whether your focus is global or local, we expect provocative originality, fi ne writing, and invigorating argument. We're looking for fresh writing that engages both our hearts and minds about what matters most to you in contemporary medicine.
We invite submissions from anyone around the world working in a health-related fi eld, whether you're a student, established in mid-career, or approaching the end of a lifetime of service in health care or biomedical science. Allow your imagination the freedom to develop your idea into the informal prose of an excellent essay. Essays of no more than 2000 words should be submitted via The Lancet's electronic submission system by Oct 26, 2015, with "Wakley Prize" selected as the publication type. Essays should not contain any information that might identify individual patients. Entries will be anonymised, and judged by the editors of The Lancet. The winner of the Wakley Prize will receive £2000, and the essay will be published in The Lancet and feature in our podcast. We will only accept one submission per author. We look forward to reading your essays and fi nding out what you know and why it matters.
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Depression remains a disabling condition with high prevalence and a large clinical burden. Despite the increased use of drugs, the long-term outcome of mood disorders has not improved in the modern era. 11 Having an alternative non-medication strategy to reduce relapse is an important means to help patients with depression. 
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